Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
110 hedge funds and large institutions have $155M invested in Adverum Biotechnologies in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 39 reducing their positions, and 20 closing their positions.
182% more call options, than puts
Call options by funds: $5.78M | Put options by funds: $2.05M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.96% less ownership
Funds ownership: 8.09% → 7.13% (-0.96%)
7% less funds holding
Funds holding: 118 → 110 (-8)
13% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 39
35% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 20
45% less capital invested
Capital invested by funds: $279M → $155M (-$125M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$2.16M |
| 2 |
Two Sigma Advisers
New York
|
+$2.02M |
| 3 |
Millennium Management
New York
|
+$1.95M |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.93M |
| 5 |
Morgan Stanley
New York
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$19.2M |
| 2 |
DM
Deerfield Management
New York
|
-$9.89M |
| 3 |
Citigroup
New York
|
-$1.72M |
| 4 |
BlackRock
New York
|
-$1.4M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.36M |
ADVM Hedge Fund Activity: Q3 2021 in Review
110 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2021, worth a combined $155M — down 45% from $279M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ADVM and 13 opened new positions — a net loss of 7 holders — while 39 trimmed existing stakes and 34 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $2.16M. The largest seller was State Street, cutting an estimated $19.2M.
- 110 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2021, down from 118 in Q2 2021.
- Funds reported $155M of Adverum Biotechnologies stock for Q3 2021, down 45% quarter-over-quarter.
- 13 funds opened new Adverum Biotechnologies positions in Q3 2021 and 20 closed out, a net change of -7 holders.
- The largest Adverum Biotechnologies buyer in Q3 2021 was HRT Financial, an estimated $2.16M added.
- The largest Adverum Biotechnologies seller in Q3 2021 was State Street, an estimated $19.2M sold.
Based on aggregated 13F filings for Q3 2021.